CONNECT WITH US
HealthTech

HealthTech

Metastatic pancreatic cancer responds well to treatment with combination of daraxonrasib and chemotherapy

Medical Xpress logo

Published on

Add as a preferred source on Google
Metastatic pancreatic cancer responds well to treatment with combination of daraxonrasib and chemotherapy

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

Daraxonrasib combined with chemotherapy caused substantial tumor shrinkage in patients with pancreatic cancer that had spread to other parts of the body, according to new results from a Phase I/II clinical trial.

In a presentation of the results from the RMC-GI-102 trial at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain, the principal investigator said the drug combination not only shrank tumors but also showed encouraging prolonged disease control when used in patients who had not previously received treatment for metastatic disease.

Dr. Wungki Park, a gastrointestinal medical oncologist at Memorial Sloan Kettering Cancer Center, New York City, U.S., said, "Pancreatic cancer remains one of the most challenging cancers to treat, particularly because more than half of patients present with disease that has already spread to other organs. We need effective treatments that can achieve deep responses and prolong disease control to curb this aggressively devastating disease.

"For most patients with previously untreated metastatic pancreatic cancer, chemotherapy remains the foundation of treatment. Although chemotherapy can shrink tumors by a modest amount and help some patients, the cancer frequently develops resistance and begins growing again."

Most patients with metastatic pancreatic cancer treated with standard chemotherapy survive for between eight and 11 months, and only 3% are alive five years after diagnosis. Tumor shrinkage is seen in only 23%–42% of patients treated with chemotherapy, and most tumors start to grow again after five to six months.


Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.